| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
- 13-Methylberberine chloride targets adipogenic transcription factors (PPARγ, C/EBPα) and AMP-activated protein kinase (AMPK) in 3T3-L1 cells [1]
- 13-Methylberberine chloride targets inflammatory mediators (COX-II, iNOS) and pro-inflammatory cytokines (TNF-α, IL-12) in LPS-stimulated macrophages[3] |
|---|---|
| ln Vitro |
- Anti-adipogenic activity in 3T3-L1 cells: Treatment with 13-Methylberberine chloride (1–10 μM) during adipocyte differentiation (days 0–8) dose-dependently reduced lipid accumulation (by 32–68% vs. control, measured via Oil Red O staining). It downregulated mRNA levels of PPARγ (by 45–72%) and C/EBPα (by 38–65%) at day 8, and decreased protein expression of these adipogenic markers (by 40–68% for PPARγ, 35–62% for C/EBPα) via Western blot. It also increased AMPK phosphorylation (by 2.1–3.5-fold vs. control) at day 4, indicating activation of the AMPK pathway [1]
- Cytotoxic activity in cancer and normal cells: 13-Methylberberine chloride showed selective cytotoxicity against human cancer cell lines: IC50 = 12.3 μM (HepG2 hepatoma), 15.7 μM (MCF-7 breast cancer), 18.2 μM (A549 lung cancer). It exhibited lower toxicity to normal cells: IC50 = 35.6 μM (normal human hepatocytes), 42.1 μM (normal human lung fibroblasts) (measured via MTT assay, 72 h treatment) [2] - Anti-inflammatory activity in LPS-stimulated macrophages: 13-Methylberberine chloride (5–20 μM) treatment for 24 h reduced LPS-induced (1 μg/mL) COX-II protein expression (by 38–70%) and iNOS protein expression (by 42–68%) in RAW 264.7 macrophages. It also decreased secretion of TNF-α (by 45–75%) and IL-12 (by 35–65%) into culture supernatants (measured via ELISA) [3] |
| Cell Assay |
- 3T3-L1 Adipocyte Differentiation Assay: 3T3-L1 pre-adipocytes were seeded in 6-well plates (2×10⁴ cells/well) and cultured to confluence (day 0). Differentiation was induced with a cocktail containing insulin, dexamethasone, and IBMX from day 0 to day 2, then maintained with insulin alone from day 2 to day 8. 13-Methylberberine chloride (1–10 μM) was added daily from day 0 to day 8. On day 8, cells were fixed with formaldehyde, stained with Oil Red O, and lipid content was quantified by extracting dye and measuring absorbance at 510 nm. For Western blot/qPCR, cells were lysed on day 4 (AMPK) or day 8 (PPARγ/C/EBPα) to detect protein/mRNA expression [1]
- MTT Cytotoxicity Assay: Cancer cells (HepG2, MCF-7, A549) and normal cells (human hepatocytes, lung fibroblasts) were seeded in 96-well plates (5×10³ cells/well) and cultured overnight. 13-Methylberberine chloride (0.1–100 μM) was added, and cells were incubated for 72 h. MTT reagent was added, and after 4 h, formazan crystals were dissolved. Absorbance at 570 nm was measured, and IC50 values were calculated using dose-response curves [2] - RAW 264.7 Macrophage Inflammation Assay: RAW 264.7 cells were seeded in 6-well plates (5×10⁵ cells/well) and cultured overnight. Cells were pre-treated with 13-Methylberberine chloride (5–20 μM) for 1 h, then stimulated with LPS (1 μg/mL) for 24 h. For Western blot, cells were lysed to detect COX-II/iNOS protein. For ELISA, culture supernatants were collected to measure TNF-α/IL-12 concentrations [3] |
| Toxicity/Toxicokinetics |
In vitro cytotoxicity: As described in the “In vitro” section, 13-methylberberine chloride exhibited selective cytotoxicity against cancer cells, with an IC50 value 2-3 times higher than that of normal cells, indicating good in vitro safety [2]. - No in vitro cytotoxicity at anti-lipogenesis/anti-inflammatory doses: 13-methylberberine chloride at concentrations up to 10 μM (anti-lipogenesis) or 20 μM (anti-inflammatory) did not reduce the viability of 3T3-L1 cells or RAW 264.7 macrophages (MTT assay: viability >90% vs. control group) [1, 3].
|
| References | |
| Additional Infomation |
13-Methylberberine chloride exhibits stronger anti-lipogenic activity than berberine: at a concentration of 10 μM, it reduces lipid accumulation in 3T3-L1 cells by 68%, while berberine at the same concentration only reduces it by 42%. This may be due to its enhanced regulatory effect on PPARγ/C/EBPα and AMPK [1]. As a protoberberine alkaloid analog, 13-methylberberine chloride retains the anti-inflammatory properties of berberine, but with greater potency: at a concentration of 10 μM, it inhibits the secretion of TNF-α in LPS-stimulated macrophages by 62%, while berberine only inhibits it by 38% [3]. The selective cytotoxicity of 13-methylberberine chloride suggests its potential as an anticancer drug, with less off-target effect on normal tissues [2].
|
| Molecular Formula |
C21H20CLNO4
|
|---|---|
| Molecular Weight |
385.8408
|
| Exact Mass |
385.108
|
| CAS # |
54260-72-9
|
| PubChem CID |
148670
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0.408
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
27
|
| Complexity |
516
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MLEFNGNLISNJEQ-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C21H20NO4.ClH/c1-12-14-4-5-17(23-2)21(24-3)16(14)10-22-7-6-13-8-18-19(26-11-25-18)9-15(13)20(12)22;/h4-5,8-10H,6-7,11H2,1-3H3;1H/q+1;/p-1
|
| Chemical Name |
16,17-dimethoxy-21-methyl-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~51.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (5.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2 mg/mL (5.18 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5917 mL | 12.9587 mL | 25.9175 mL | |
| 5 mM | 0.5183 mL | 2.5917 mL | 5.1835 mL | |
| 10 mM | 0.2592 mL | 1.2959 mL | 2.5917 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
